nodes	percent_of_prediction	percent_of_DWPC	metapath
Nefazodone—HTR1A—stomach cancer	0.374	1	CbGaD
Nefazodone—ABCB1—Mitomycin—stomach cancer	0.0684	0.212	CbGbCtD
Nefazodone—CYP3A7-CYP3A51P—Irinotecan—stomach cancer	0.0359	0.112	CbGbCtD
Nefazodone—CYP3A7—Irinotecan—stomach cancer	0.0359	0.112	CbGbCtD
Nefazodone—CYP3A5—Irinotecan—stomach cancer	0.0269	0.0837	CbGbCtD
Nefazodone—CYP3A7-CYP3A51P—Docetaxel—stomach cancer	0.0263	0.0818	CbGbCtD
Nefazodone—CYP3A7—Docetaxel—stomach cancer	0.0263	0.0818	CbGbCtD
Nefazodone—CYP3A5—Docetaxel—stomach cancer	0.0197	0.0614	CbGbCtD
Nefazodone—ABCB1—Irinotecan—stomach cancer	0.0175	0.0545	CbGbCtD
Nefazodone—ABCB1—Docetaxel—stomach cancer	0.0129	0.0399	CbGbCtD
Nefazodone—CYP3A4—Irinotecan—stomach cancer	0.0105	0.0327	CbGbCtD
Nefazodone—ABCB1—Doxorubicin—stomach cancer	0.00958	0.0298	CbGbCtD
Nefazodone—ABCB1—Methotrexate—stomach cancer	0.00928	0.0288	CbGbCtD
Nefazodone—CYP2D6—Doxorubicin—stomach cancer	0.00903	0.0281	CbGbCtD
Nefazodone—CYP3A4—Docetaxel—stomach cancer	0.0077	0.0239	CbGbCtD
Nefazodone—CYP3A4—Doxorubicin—stomach cancer	0.00574	0.0178	CbGbCtD
Nefazodone—HTR2A—myenteric nerve plexus—stomach cancer	0.00444	0.136	CbGeAlD
Nefazodone—HTR2A—vagus nerve—stomach cancer	0.00296	0.0906	CbGeAlD
Nefazodone—HTR2A—vein—stomach cancer	0.00286	0.0876	CbGeAlD
Nefazodone—SLC6A3—hematopoietic system—stomach cancer	0.000998	0.0305	CbGeAlD
Nefazodone—CYP3A7—endocrine gland—stomach cancer	0.000974	0.0298	CbGeAlD
Nefazodone—SLC6A4—hematopoietic system—stomach cancer	0.000914	0.028	CbGeAlD
Nefazodone—HTR2A—blood vessel—stomach cancer	0.000909	0.0278	CbGeAlD
Nefazodone—CYP3A7—liver—stomach cancer	0.000879	0.0269	CbGeAlD
Nefazodone—HTR1A—hematopoietic system—stomach cancer	0.000812	0.0248	CbGeAlD
Nefazodone—ADRA1A—hematopoietic system—stomach cancer	0.000748	0.0229	CbGeAlD
Nefazodone—CYP3A7-CYP3A51P—liver—stomach cancer	0.000747	0.0228	CbGeAlD
Nefazodone—ADRA1A—epithelium—stomach cancer	0.000684	0.0209	CbGeAlD
Nefazodone—SLC6A4—digestive system—stomach cancer	0.000636	0.0194	CbGeAlD
Nefazodone—CYP3A5—hematopoietic system—stomach cancer	0.000597	0.0182	CbGeAlD
Nefazodone—ABCB1—blood vessel—stomach cancer	0.000595	0.0182	CbGeAlD
Nefazodone—ADRA2A—hematopoietic system—stomach cancer	0.000569	0.0174	CbGeAlD
Nefazodone—ADRA1A—lymphoid tissue—stomach cancer	0.000527	0.0161	CbGeAlD
Nefazodone—SLC6A4—endocrine gland—stomach cancer	0.000525	0.0161	CbGeAlD
Nefazodone—CYP3A5—pancreas—stomach cancer	0.000486	0.0149	CbGeAlD
Nefazodone—HTR2A—hematopoietic system—stomach cancer	0.000484	0.0148	CbGeAlD
Nefazodone—HTR1A—endocrine gland—stomach cancer	0.000466	0.0143	CbGeAlD
Nefazodone—ADRA2A—pancreas—stomach cancer	0.000463	0.0142	CbGeAlD
Nefazodone—SLC6A2—endocrine gland—stomach cancer	0.000463	0.0141	CbGeAlD
Nefazodone—CYP3A4—hematopoietic system—stomach cancer	0.000448	0.0137	CbGeAlD
Nefazodone—HTR2A—epithelium—stomach cancer	0.000442	0.0135	CbGeAlD
Nefazodone—CYP2D6—hematopoietic system—stomach cancer	0.000441	0.0135	CbGeAlD
Nefazodone—ADRA1A—endocrine gland—stomach cancer	0.00043	0.0131	CbGeAlD
Nefazodone—HTR2A—smooth muscle tissue—stomach cancer	0.000426	0.013	CbGeAlD
Nefazodone—CYP3A5—digestive system—stomach cancer	0.000415	0.0127	CbGeAlD
Nefazodone—ADRA1A—liver—stomach cancer	0.000388	0.0119	CbGeAlD
Nefazodone—Aripiprazole—ADRB1—stomach cancer	0.000356	0.155	CrCbGaD
Nefazodone—CYP3A5—endocrine gland—stomach cancer	0.000343	0.0105	CbGeAlD
Nefazodone—HTR2A—digestive system—stomach cancer	0.000336	0.0103	CbGeAlD
Nefazodone—ADRA2A—endocrine gland—stomach cancer	0.000327	0.01	CbGeAlD
Nefazodone—SLC6A2—lymph node—stomach cancer	0.00032	0.00978	CbGeAlD
Nefazodone—Aripiprazole—HTR1A—stomach cancer	0.000318	0.139	CrCbGaD
Nefazodone—ABCB1—hematopoietic system—stomach cancer	0.000317	0.00969	CbGeAlD
Nefazodone—Trazodone—HTR1A—stomach cancer	0.000317	0.138	CrCbGaD
Nefazodone—CYP3A4—digestive system—stomach cancer	0.000311	0.00952	CbGeAlD
Nefazodone—CYP3A5—liver—stomach cancer	0.000309	0.00946	CbGeAlD
Nefazodone—CYP2D6—digestive system—stomach cancer	0.000306	0.00937	CbGeAlD
Nefazodone—Thioproperazine—HTR1A—stomach cancer	0.000302	0.132	CrCbGaD
Nefazodone—ABCB1—epithelium—stomach cancer	0.00029	0.00886	CbGeAlD
Nefazodone—HTR2A—endocrine gland—stomach cancer	0.000278	0.0085	CbGeAlD
Nefazodone—ABCB1—pancreas—stomach cancer	0.000258	0.00789	CbGeAlD
Nefazodone—CYP3A4—endocrine gland—stomach cancer	0.000257	0.00787	CbGeAlD
Nefazodone—Fluphenazine—HTR1A—stomach cancer	0.000257	0.112	CrCbGaD
Nefazodone—CYP2D6—endocrine gland—stomach cancer	0.000253	0.00774	CbGeAlD
Nefazodone—HTR2A—liver—stomach cancer	0.000251	0.00766	CbGeAlD
Nefazodone—CYP3A4—liver—stomach cancer	0.000232	0.0071	CbGeAlD
Nefazodone—CYP2D6—liver—stomach cancer	0.000228	0.00698	CbGeAlD
Nefazodone—ADRA2A—lymph node—stomach cancer	0.000226	0.00691	CbGeAlD
Nefazodone—ABCB1—lymphoid tissue—stomach cancer	0.000223	0.00683	CbGeAlD
Nefazodone—ABCB1—digestive system—stomach cancer	0.00022	0.00674	CbGeAlD
Nefazodone—Trifluoperazine—HTR1A—stomach cancer	0.000205	0.0895	CrCbGaD
Nefazodone—ABCB1—bone marrow—stomach cancer	0.000203	0.00621	CbGeAlD
Nefazodone—Perphenazine—HTR1A—stomach cancer	0.000203	0.0885	CrCbGaD
Nefazodone—Quetiapine—HTR1A—stomach cancer	0.000199	0.0868	CrCbGaD
Nefazodone—ABCB1—endocrine gland—stomach cancer	0.000182	0.00557	CbGeAlD
Nefazodone—ABCB1—liver—stomach cancer	0.000164	0.00502	CbGeAlD
Nefazodone—Thioproperazine—ALB—stomach cancer	0.000135	0.0591	CrCbGaD
Nefazodone—ABCB1—lymph node—stomach cancer	0.000126	0.00385	CbGeAlD
Nefazodone—Tinnitus—Methotrexate—stomach cancer	0.000119	0.000598	CcSEcCtD
Nefazodone—Tachycardia—Capecitabine—stomach cancer	0.000119	0.000598	CcSEcCtD
Nefazodone—Hypoaesthesia—Epirubicin—stomach cancer	0.000119	0.000597	CcSEcCtD
Nefazodone—Pharyngitis—Epirubicin—stomach cancer	0.000118	0.000596	CcSEcCtD
Nefazodone—Sweating—Doxorubicin—stomach cancer	0.000118	0.000593	CcSEcCtD
Nefazodone—Hyperhidrosis—Capecitabine—stomach cancer	0.000117	0.000592	CcSEcCtD
Nefazodone—Oedema peripheral—Epirubicin—stomach cancer	0.000117	0.000592	CcSEcCtD
Nefazodone—Hypotension—Docetaxel—stomach cancer	0.000117	0.000591	CcSEcCtD
Nefazodone—Haematuria—Doxorubicin—stomach cancer	0.000117	0.00059	CcSEcCtD
Nefazodone—Epistaxis—Doxorubicin—stomach cancer	0.000116	0.000584	CcSEcCtD
Nefazodone—Anorexia—Capecitabine—stomach cancer	0.000116	0.000584	CcSEcCtD
Nefazodone—Vomiting—Irinotecan—stomach cancer	0.000115	0.000582	CcSEcCtD
Nefazodone—Sinusitis—Doxorubicin—stomach cancer	0.000115	0.000581	CcSEcCtD
Nefazodone—Dizziness—Fluorouracil—stomach cancer	0.000115	0.000579	CcSEcCtD
Nefazodone—Visual impairment—Epirubicin—stomach cancer	0.000115	0.000579	CcSEcCtD
Nefazodone—Rash—Irinotecan—stomach cancer	0.000114	0.000577	CcSEcCtD
Nefazodone—Dermatitis—Irinotecan—stomach cancer	0.000114	0.000576	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Docetaxel—stomach cancer	0.000114	0.000576	CcSEcCtD
Nefazodone—Chills—Methotrexate—stomach cancer	0.000114	0.000576	CcSEcCtD
Nefazodone—Headache—Irinotecan—stomach cancer	0.000114	0.000573	CcSEcCtD
Nefazodone—Hypotension—Capecitabine—stomach cancer	0.000114	0.000572	CcSEcCtD
Nefazodone—Insomnia—Docetaxel—stomach cancer	0.000114	0.000572	CcSEcCtD
Nefazodone—Paraesthesia—Docetaxel—stomach cancer	0.000113	0.000568	CcSEcCtD
Nefazodone—Erythema multiforme—Epirubicin—stomach cancer	0.000113	0.000568	CcSEcCtD
Nefazodone—Alopecia—Methotrexate—stomach cancer	0.000113	0.000567	CcSEcCtD
Nefazodone—Bradycardia—Doxorubicin—stomach cancer	0.000112	0.000566	CcSEcCtD
Nefazodone—Dyspnoea—Docetaxel—stomach cancer	0.000112	0.000564	CcSEcCtD
Nefazodone—Somnolence—Docetaxel—stomach cancer	0.000112	0.000562	CcSEcCtD
Nefazodone—Tinnitus—Epirubicin—stomach cancer	0.000111	0.00056	CcSEcCtD
Nefazodone—Haemoglobin—Doxorubicin—stomach cancer	0.000111	0.000558	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Capecitabine—stomach cancer	0.000111	0.000558	CcSEcCtD
Nefazodone—Flushing—Epirubicin—stomach cancer	0.000111	0.000557	CcSEcCtD
Nefazodone—Vomiting—Fluorouracil—stomach cancer	0.000111	0.000557	CcSEcCtD
Nefazodone—Rhinitis—Doxorubicin—stomach cancer	0.000111	0.000557	CcSEcCtD
Nefazodone—Dyspepsia—Docetaxel—stomach cancer	0.00011	0.000557	CcSEcCtD
Nefazodone—Hepatitis—Doxorubicin—stomach cancer	0.00011	0.000556	CcSEcCtD
Nefazodone—Haemorrhage—Doxorubicin—stomach cancer	0.00011	0.000556	CcSEcCtD
Nefazodone—Insomnia—Capecitabine—stomach cancer	0.00011	0.000554	CcSEcCtD
Nefazodone—Hypoaesthesia—Doxorubicin—stomach cancer	0.00011	0.000553	CcSEcCtD
Nefazodone—Rash—Fluorouracil—stomach cancer	0.00011	0.000553	CcSEcCtD
Nefazodone—Dermatitis—Fluorouracil—stomach cancer	0.00011	0.000552	CcSEcCtD
Nefazodone—Pharyngitis—Doxorubicin—stomach cancer	0.000109	0.000551	CcSEcCtD
Nefazodone—Paraesthesia—Capecitabine—stomach cancer	0.000109	0.00055	CcSEcCtD
Nefazodone—Decreased appetite—Docetaxel—stomach cancer	0.000109	0.00055	CcSEcCtD
Nefazodone—Headache—Fluorouracil—stomach cancer	0.000109	0.000549	CcSEcCtD
Nefazodone—Oedema peripheral—Doxorubicin—stomach cancer	0.000109	0.000547	CcSEcCtD
Nefazodone—Dysgeusia—Methotrexate—stomach cancer	0.000109	0.000547	CcSEcCtD
Nefazodone—Dyspnoea—Capecitabine—stomach cancer	0.000108	0.000546	CcSEcCtD
Nefazodone—Nausea—Irinotecan—stomach cancer	0.000108	0.000543	CcSEcCtD
Nefazodone—Pain—Docetaxel—stomach cancer	0.000107	0.000541	CcSEcCtD
Nefazodone—Constipation—Docetaxel—stomach cancer	0.000107	0.000541	CcSEcCtD
Nefazodone—Back pain—Methotrexate—stomach cancer	0.000107	0.00054	CcSEcCtD
Nefazodone—Dyspepsia—Capecitabine—stomach cancer	0.000107	0.000539	CcSEcCtD
Nefazodone—Chills—Epirubicin—stomach cancer	0.000107	0.000539	CcSEcCtD
Nefazodone—Visual impairment—Doxorubicin—stomach cancer	0.000106	0.000535	CcSEcCtD
Nefazodone—Decreased appetite—Capecitabine—stomach cancer	0.000106	0.000532	CcSEcCtD
Nefazodone—Alopecia—Epirubicin—stomach cancer	0.000105	0.000531	CcSEcCtD
Nefazodone—Vision blurred—Methotrexate—stomach cancer	0.000104	0.000526	CcSEcCtD
Nefazodone—Erythema multiforme—Doxorubicin—stomach cancer	0.000104	0.000525	CcSEcCtD
Nefazodone—Pain—Capecitabine—stomach cancer	0.000104	0.000524	CcSEcCtD
Nefazodone—Constipation—Capecitabine—stomach cancer	0.000104	0.000524	CcSEcCtD
Nefazodone—Feeling abnormal—Docetaxel—stomach cancer	0.000103	0.000521	CcSEcCtD
Nefazodone—Nausea—Fluorouracil—stomach cancer	0.000103	0.000521	CcSEcCtD
Nefazodone—Ill-defined disorder—Methotrexate—stomach cancer	0.000103	0.000518	CcSEcCtD
Nefazodone—Tinnitus—Doxorubicin—stomach cancer	0.000103	0.000518	CcSEcCtD
Nefazodone—Gastrointestinal pain—Docetaxel—stomach cancer	0.000103	0.000517	CcSEcCtD
Nefazodone—Anaemia—Methotrexate—stomach cancer	0.000102	0.000516	CcSEcCtD
Nefazodone—Flushing—Doxorubicin—stomach cancer	0.000102	0.000516	CcSEcCtD
Nefazodone—Flatulence—Epirubicin—stomach cancer	0.000102	0.000515	CcSEcCtD
Nefazodone—Dysgeusia—Epirubicin—stomach cancer	0.000102	0.000512	CcSEcCtD
Nefazodone—Back pain—Epirubicin—stomach cancer	0.0001	0.000506	CcSEcCtD
Nefazodone—Feeling abnormal—Capecitabine—stomach cancer	0.0001	0.000505	CcSEcCtD
Nefazodone—Malaise—Methotrexate—stomach cancer	0.0001	0.000504	CcSEcCtD
Nefazodone—Muscle spasms—Epirubicin—stomach cancer	9.97e-05	0.000503	CcSEcCtD
Nefazodone—Vertigo—Methotrexate—stomach cancer	9.96e-05	0.000502	CcSEcCtD
Nefazodone—Gastrointestinal pain—Capecitabine—stomach cancer	9.94e-05	0.000501	CcSEcCtD
Nefazodone—Body temperature increased—Docetaxel—stomach cancer	9.92e-05	0.0005	CcSEcCtD
Nefazodone—Abdominal pain—Docetaxel—stomach cancer	9.92e-05	0.0005	CcSEcCtD
Nefazodone—Leukopenia—Methotrexate—stomach cancer	9.92e-05	0.0005	CcSEcCtD
Nefazodone—Chills—Doxorubicin—stomach cancer	9.89e-05	0.000499	CcSEcCtD
Nefazodone—Vision blurred—Epirubicin—stomach cancer	9.78e-05	0.000493	CcSEcCtD
Nefazodone—Alopecia—Doxorubicin—stomach cancer	9.74e-05	0.000491	CcSEcCtD
Nefazodone—Cough—Methotrexate—stomach cancer	9.67e-05	0.000487	CcSEcCtD
Nefazodone—Urticaria—Capecitabine—stomach cancer	9.65e-05	0.000486	CcSEcCtD
Nefazodone—Ill-defined disorder—Epirubicin—stomach cancer	9.62e-05	0.000485	CcSEcCtD
Nefazodone—Abdominal pain—Capecitabine—stomach cancer	9.61e-05	0.000484	CcSEcCtD
Nefazodone—Body temperature increased—Capecitabine—stomach cancer	9.61e-05	0.000484	CcSEcCtD
Nefazodone—Convulsion—Methotrexate—stomach cancer	9.6e-05	0.000484	CcSEcCtD
Nefazodone—Anaemia—Epirubicin—stomach cancer	9.59e-05	0.000483	CcSEcCtD
Nefazodone—Agitation—Epirubicin—stomach cancer	9.53e-05	0.00048	CcSEcCtD
Nefazodone—Flatulence—Doxorubicin—stomach cancer	9.46e-05	0.000477	CcSEcCtD
Nefazodone—Chest pain—Methotrexate—stomach cancer	9.44e-05	0.000476	CcSEcCtD
Nefazodone—Myalgia—Methotrexate—stomach cancer	9.44e-05	0.000476	CcSEcCtD
Nefazodone—Arthralgia—Methotrexate—stomach cancer	9.44e-05	0.000476	CcSEcCtD
Nefazodone—Dysgeusia—Doxorubicin—stomach cancer	9.4e-05	0.000474	CcSEcCtD
Nefazodone—Malaise—Epirubicin—stomach cancer	9.35e-05	0.000471	CcSEcCtD
Nefazodone—Discomfort—Methotrexate—stomach cancer	9.32e-05	0.00047	CcSEcCtD
Nefazodone—Vertigo—Epirubicin—stomach cancer	9.32e-05	0.00047	CcSEcCtD
Nefazodone—Syncope—Epirubicin—stomach cancer	9.3e-05	0.000469	CcSEcCtD
Nefazodone—Leukopenia—Epirubicin—stomach cancer	9.29e-05	0.000468	CcSEcCtD
Nefazodone—Back pain—Doxorubicin—stomach cancer	9.28e-05	0.000468	CcSEcCtD
Nefazodone—Hypersensitivity—Docetaxel—stomach cancer	9.25e-05	0.000466	CcSEcCtD
Nefazodone—Muscle spasms—Doxorubicin—stomach cancer	9.23e-05	0.000465	CcSEcCtD
Nefazodone—Palpitations—Epirubicin—stomach cancer	9.17e-05	0.000462	CcSEcCtD
Nefazodone—Confusional state—Methotrexate—stomach cancer	9.12e-05	0.00046	CcSEcCtD
Nefazodone—Loss of consciousness—Epirubicin—stomach cancer	9.12e-05	0.000459	CcSEcCtD
Nefazodone—Cough—Epirubicin—stomach cancer	9.05e-05	0.000456	CcSEcCtD
Nefazodone—Anaphylactic shock—Methotrexate—stomach cancer	9.05e-05	0.000456	CcSEcCtD
Nefazodone—Vision blurred—Doxorubicin—stomach cancer	9.05e-05	0.000456	CcSEcCtD
Nefazodone—Asthenia—Docetaxel—stomach cancer	9.01e-05	0.000454	CcSEcCtD
Nefazodone—Convulsion—Epirubicin—stomach cancer	8.99e-05	0.000453	CcSEcCtD
Nefazodone—Infection—Methotrexate—stomach cancer	8.99e-05	0.000453	CcSEcCtD
Nefazodone—Hypertension—Epirubicin—stomach cancer	8.96e-05	0.000451	CcSEcCtD
Nefazodone—Hypersensitivity—Capecitabine—stomach cancer	8.95e-05	0.000451	CcSEcCtD
Nefazodone—Ill-defined disorder—Doxorubicin—stomach cancer	8.91e-05	0.000449	CcSEcCtD
Nefazodone—Pruritus—Docetaxel—stomach cancer	8.88e-05	0.000447	CcSEcCtD
Nefazodone—Anaemia—Doxorubicin—stomach cancer	8.87e-05	0.000447	CcSEcCtD
Nefazodone—Thrombocytopenia—Methotrexate—stomach cancer	8.86e-05	0.000446	CcSEcCtD
Nefazodone—Chest pain—Epirubicin—stomach cancer	8.83e-05	0.000445	CcSEcCtD
Nefazodone—Arthralgia—Epirubicin—stomach cancer	8.83e-05	0.000445	CcSEcCtD
Nefazodone—Myalgia—Epirubicin—stomach cancer	8.83e-05	0.000445	CcSEcCtD
Nefazodone—Agitation—Doxorubicin—stomach cancer	8.82e-05	0.000444	CcSEcCtD
Nefazodone—Anxiety—Epirubicin—stomach cancer	8.8e-05	0.000443	CcSEcCtD
Nefazodone—Hyperhidrosis—Methotrexate—stomach cancer	8.75e-05	0.000441	CcSEcCtD
Nefazodone—Discomfort—Epirubicin—stomach cancer	8.73e-05	0.00044	CcSEcCtD
Nefazodone—Asthenia—Capecitabine—stomach cancer	8.72e-05	0.000439	CcSEcCtD
Nefazodone—Malaise—Doxorubicin—stomach cancer	8.66e-05	0.000436	CcSEcCtD
Nefazodone—Dry mouth—Epirubicin—stomach cancer	8.64e-05	0.000435	CcSEcCtD
Nefazodone—Vertigo—Doxorubicin—stomach cancer	8.62e-05	0.000435	CcSEcCtD
Nefazodone—Anorexia—Methotrexate—stomach cancer	8.62e-05	0.000435	CcSEcCtD
Nefazodone—Syncope—Doxorubicin—stomach cancer	8.61e-05	0.000434	CcSEcCtD
Nefazodone—Pruritus—Capecitabine—stomach cancer	8.6e-05	0.000433	CcSEcCtD
Nefazodone—Leukopenia—Doxorubicin—stomach cancer	8.59e-05	0.000433	CcSEcCtD
Nefazodone—Diarrhoea—Docetaxel—stomach cancer	8.59e-05	0.000433	CcSEcCtD
Nefazodone—Confusional state—Epirubicin—stomach cancer	8.54e-05	0.00043	CcSEcCtD
Nefazodone—Palpitations—Doxorubicin—stomach cancer	8.48e-05	0.000427	CcSEcCtD
Nefazodone—Oedema—Epirubicin—stomach cancer	8.47e-05	0.000427	CcSEcCtD
Nefazodone—Anaphylactic shock—Epirubicin—stomach cancer	8.47e-05	0.000427	CcSEcCtD
Nefazodone—Hypotension—Methotrexate—stomach cancer	8.45e-05	0.000426	CcSEcCtD
Nefazodone—Loss of consciousness—Doxorubicin—stomach cancer	8.44e-05	0.000425	CcSEcCtD
Nefazodone—Infection—Epirubicin—stomach cancer	8.41e-05	0.000424	CcSEcCtD
Nefazodone—Cough—Doxorubicin—stomach cancer	8.38e-05	0.000422	CcSEcCtD
Nefazodone—Shock—Epirubicin—stomach cancer	8.33e-05	0.00042	CcSEcCtD
Nefazodone—Convulsion—Doxorubicin—stomach cancer	8.32e-05	0.000419	CcSEcCtD
Nefazodone—Diarrhoea—Capecitabine—stomach cancer	8.31e-05	0.000419	CcSEcCtD
Nefazodone—Dizziness—Docetaxel—stomach cancer	8.3e-05	0.000418	CcSEcCtD
Nefazodone—Thrombocytopenia—Epirubicin—stomach cancer	8.29e-05	0.000418	CcSEcCtD
Nefazodone—Hypertension—Doxorubicin—stomach cancer	8.29e-05	0.000418	CcSEcCtD
Nefazodone—Tachycardia—Epirubicin—stomach cancer	8.26e-05	0.000416	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Methotrexate—stomach cancer	8.24e-05	0.000415	CcSEcCtD
Nefazodone—Hyperhidrosis—Epirubicin—stomach cancer	8.18e-05	0.000412	CcSEcCtD
Nefazodone—Insomnia—Methotrexate—stomach cancer	8.18e-05	0.000412	CcSEcCtD
Nefazodone—Arthralgia—Doxorubicin—stomach cancer	8.17e-05	0.000412	CcSEcCtD
Nefazodone—Myalgia—Doxorubicin—stomach cancer	8.17e-05	0.000412	CcSEcCtD
Nefazodone—Chest pain—Doxorubicin—stomach cancer	8.17e-05	0.000412	CcSEcCtD
Nefazodone—Anxiety—Doxorubicin—stomach cancer	8.14e-05	0.00041	CcSEcCtD
Nefazodone—Paraesthesia—Methotrexate—stomach cancer	8.12e-05	0.000409	CcSEcCtD
Nefazodone—Discomfort—Doxorubicin—stomach cancer	8.07e-05	0.000407	CcSEcCtD
Nefazodone—Anorexia—Epirubicin—stomach cancer	8.07e-05	0.000407	CcSEcCtD
Nefazodone—Dyspnoea—Methotrexate—stomach cancer	8.07e-05	0.000406	CcSEcCtD
Nefazodone—Somnolence—Methotrexate—stomach cancer	8.04e-05	0.000405	CcSEcCtD
Nefazodone—Dizziness—Capecitabine—stomach cancer	8.04e-05	0.000405	CcSEcCtD
Nefazodone—Dry mouth—Doxorubicin—stomach cancer	7.99e-05	0.000403	CcSEcCtD
Nefazodone—Vomiting—Docetaxel—stomach cancer	7.98e-05	0.000402	CcSEcCtD
Nefazodone—Dyspepsia—Methotrexate—stomach cancer	7.96e-05	0.000401	CcSEcCtD
Nefazodone—Rash—Docetaxel—stomach cancer	7.91e-05	0.000399	CcSEcCtD
Nefazodone—Hypotension—Epirubicin—stomach cancer	7.91e-05	0.000399	CcSEcCtD
Nefazodone—Dermatitis—Docetaxel—stomach cancer	7.91e-05	0.000398	CcSEcCtD
Nefazodone—Confusional state—Doxorubicin—stomach cancer	7.9e-05	0.000398	CcSEcCtD
Nefazodone—Decreased appetite—Methotrexate—stomach cancer	7.86e-05	0.000396	CcSEcCtD
Nefazodone—Headache—Docetaxel—stomach cancer	7.86e-05	0.000396	CcSEcCtD
Nefazodone—Oedema—Doxorubicin—stomach cancer	7.83e-05	0.000395	CcSEcCtD
Nefazodone—Anaphylactic shock—Doxorubicin—stomach cancer	7.83e-05	0.000395	CcSEcCtD
Nefazodone—Infection—Doxorubicin—stomach cancer	7.78e-05	0.000392	CcSEcCtD
Nefazodone—Pain—Methotrexate—stomach cancer	7.74e-05	0.00039	CcSEcCtD
Nefazodone—Vomiting—Capecitabine—stomach cancer	7.73e-05	0.000389	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Epirubicin—stomach cancer	7.71e-05	0.000389	CcSEcCtD
Nefazodone—Shock—Doxorubicin—stomach cancer	7.71e-05	0.000388	CcSEcCtD
Nefazodone—Thrombocytopenia—Doxorubicin—stomach cancer	7.67e-05	0.000386	CcSEcCtD
Nefazodone—Rash—Capecitabine—stomach cancer	7.66e-05	0.000386	CcSEcCtD
Nefazodone—Insomnia—Epirubicin—stomach cancer	7.66e-05	0.000386	CcSEcCtD
Nefazodone—Dermatitis—Capecitabine—stomach cancer	7.66e-05	0.000386	CcSEcCtD
Nefazodone—Tachycardia—Doxorubicin—stomach cancer	7.65e-05	0.000385	CcSEcCtD
Nefazodone—Headache—Capecitabine—stomach cancer	7.61e-05	0.000384	CcSEcCtD
Nefazodone—Paraesthesia—Epirubicin—stomach cancer	7.6e-05	0.000383	CcSEcCtD
Nefazodone—Hyperhidrosis—Doxorubicin—stomach cancer	7.57e-05	0.000382	CcSEcCtD
Nefazodone—Dyspnoea—Epirubicin—stomach cancer	7.55e-05	0.00038	CcSEcCtD
Nefazodone—Somnolence—Epirubicin—stomach cancer	7.53e-05	0.000379	CcSEcCtD
Nefazodone—Anorexia—Doxorubicin—stomach cancer	7.47e-05	0.000376	CcSEcCtD
Nefazodone—Nausea—Docetaxel—stomach cancer	7.46e-05	0.000376	CcSEcCtD
Nefazodone—Feeling abnormal—Methotrexate—stomach cancer	7.45e-05	0.000376	CcSEcCtD
Nefazodone—Dyspepsia—Epirubicin—stomach cancer	7.45e-05	0.000376	CcSEcCtD
Nefazodone—Gastrointestinal pain—Methotrexate—stomach cancer	7.4e-05	0.000373	CcSEcCtD
Nefazodone—Decreased appetite—Epirubicin—stomach cancer	7.36e-05	0.000371	CcSEcCtD
Nefazodone—Hypotension—Doxorubicin—stomach cancer	7.32e-05	0.000369	CcSEcCtD
Nefazodone—Constipation—Epirubicin—stomach cancer	7.24e-05	0.000365	CcSEcCtD
Nefazodone—Pain—Epirubicin—stomach cancer	7.24e-05	0.000365	CcSEcCtD
Nefazodone—Nausea—Capecitabine—stomach cancer	7.22e-05	0.000364	CcSEcCtD
Nefazodone—Urticaria—Methotrexate—stomach cancer	7.19e-05	0.000362	CcSEcCtD
Nefazodone—Body temperature increased—Methotrexate—stomach cancer	7.15e-05	0.00036	CcSEcCtD
Nefazodone—Abdominal pain—Methotrexate—stomach cancer	7.15e-05	0.00036	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Doxorubicin—stomach cancer	7.14e-05	0.00036	CcSEcCtD
Nefazodone—Insomnia—Doxorubicin—stomach cancer	7.09e-05	0.000357	CcSEcCtD
Nefazodone—Paraesthesia—Doxorubicin—stomach cancer	7.03e-05	0.000354	CcSEcCtD
Nefazodone—Dyspnoea—Doxorubicin—stomach cancer	6.98e-05	0.000352	CcSEcCtD
Nefazodone—Feeling abnormal—Epirubicin—stomach cancer	6.98e-05	0.000352	CcSEcCtD
Nefazodone—Somnolence—Doxorubicin—stomach cancer	6.96e-05	0.000351	CcSEcCtD
Nefazodone—Gastrointestinal pain—Epirubicin—stomach cancer	6.92e-05	0.000349	CcSEcCtD
Nefazodone—Dyspepsia—Doxorubicin—stomach cancer	6.9e-05	0.000347	CcSEcCtD
Nefazodone—Decreased appetite—Doxorubicin—stomach cancer	6.81e-05	0.000343	CcSEcCtD
Nefazodone—Urticaria—Epirubicin—stomach cancer	6.73e-05	0.000339	CcSEcCtD
Nefazodone—Constipation—Doxorubicin—stomach cancer	6.7e-05	0.000338	CcSEcCtD
Nefazodone—Pain—Doxorubicin—stomach cancer	6.7e-05	0.000338	CcSEcCtD
Nefazodone—Abdominal pain—Epirubicin—stomach cancer	6.69e-05	0.000337	CcSEcCtD
Nefazodone—Body temperature increased—Epirubicin—stomach cancer	6.69e-05	0.000337	CcSEcCtD
Nefazodone—Hypersensitivity—Methotrexate—stomach cancer	6.67e-05	0.000336	CcSEcCtD
Nefazodone—Asthenia—Methotrexate—stomach cancer	6.49e-05	0.000327	CcSEcCtD
Nefazodone—Feeling abnormal—Doxorubicin—stomach cancer	6.46e-05	0.000325	CcSEcCtD
Nefazodone—Gastrointestinal pain—Doxorubicin—stomach cancer	6.41e-05	0.000323	CcSEcCtD
Nefazodone—Pruritus—Methotrexate—stomach cancer	6.4e-05	0.000323	CcSEcCtD
Nefazodone—Hypersensitivity—Epirubicin—stomach cancer	6.24e-05	0.000314	CcSEcCtD
Nefazodone—Urticaria—Doxorubicin—stomach cancer	6.22e-05	0.000314	CcSEcCtD
Nefazodone—Abdominal pain—Doxorubicin—stomach cancer	6.19e-05	0.000312	CcSEcCtD
Nefazodone—Body temperature increased—Doxorubicin—stomach cancer	6.19e-05	0.000312	CcSEcCtD
Nefazodone—Diarrhoea—Methotrexate—stomach cancer	6.19e-05	0.000312	CcSEcCtD
Nefazodone—Asthenia—Epirubicin—stomach cancer	6.07e-05	0.000306	CcSEcCtD
Nefazodone—Pruritus—Epirubicin—stomach cancer	5.99e-05	0.000302	CcSEcCtD
Nefazodone—Dizziness—Methotrexate—stomach cancer	5.98e-05	0.000301	CcSEcCtD
Nefazodone—Diarrhoea—Epirubicin—stomach cancer	5.79e-05	0.000292	CcSEcCtD
Nefazodone—Hypersensitivity—Doxorubicin—stomach cancer	5.77e-05	0.000291	CcSEcCtD
Nefazodone—Vomiting—Methotrexate—stomach cancer	5.75e-05	0.00029	CcSEcCtD
Nefazodone—Rash—Methotrexate—stomach cancer	5.7e-05	0.000287	CcSEcCtD
Nefazodone—Dermatitis—Methotrexate—stomach cancer	5.7e-05	0.000287	CcSEcCtD
Nefazodone—Headache—Methotrexate—stomach cancer	5.67e-05	0.000286	CcSEcCtD
Nefazodone—Asthenia—Doxorubicin—stomach cancer	5.62e-05	0.000283	CcSEcCtD
Nefazodone—Dizziness—Epirubicin—stomach cancer	5.6e-05	0.000282	CcSEcCtD
Nefazodone—Pruritus—Doxorubicin—stomach cancer	5.54e-05	0.000279	CcSEcCtD
Nefazodone—Vomiting—Epirubicin—stomach cancer	5.38e-05	0.000271	CcSEcCtD
Nefazodone—Nausea—Methotrexate—stomach cancer	5.37e-05	0.000271	CcSEcCtD
Nefazodone—Diarrhoea—Doxorubicin—stomach cancer	5.36e-05	0.00027	CcSEcCtD
Nefazodone—Rash—Epirubicin—stomach cancer	5.34e-05	0.000269	CcSEcCtD
Nefazodone—Dermatitis—Epirubicin—stomach cancer	5.33e-05	0.000269	CcSEcCtD
Nefazodone—Headache—Epirubicin—stomach cancer	5.3e-05	0.000267	CcSEcCtD
Nefazodone—Dizziness—Doxorubicin—stomach cancer	5.18e-05	0.000261	CcSEcCtD
Nefazodone—Nausea—Epirubicin—stomach cancer	5.03e-05	0.000253	CcSEcCtD
Nefazodone—Vomiting—Doxorubicin—stomach cancer	4.98e-05	0.000251	CcSEcCtD
Nefazodone—Rash—Doxorubicin—stomach cancer	4.94e-05	0.000249	CcSEcCtD
Nefazodone—Dermatitis—Doxorubicin—stomach cancer	4.93e-05	0.000249	CcSEcCtD
Nefazodone—Headache—Doxorubicin—stomach cancer	4.91e-05	0.000247	CcSEcCtD
Nefazodone—Nausea—Doxorubicin—stomach cancer	4.65e-05	0.000234	CcSEcCtD
Nefazodone—CYP2D6—Metabolism—PPP2R1A—stomach cancer	5.55e-06	7.79e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—MAPK3—stomach cancer	5.53e-06	7.76e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—MAPK1—stomach cancer	5.53e-06	7.76e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—EGFR—stomach cancer	5.53e-06	7.75e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PPARG—stomach cancer	5.5e-06	7.72e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—MAPK1—stomach cancer	5.5e-06	7.72e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—EGFR—stomach cancer	5.5e-06	7.71e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PTGS2—stomach cancer	5.49e-06	7.7e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PRKCB—stomach cancer	5.48e-06	7.68e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IL6ST—stomach cancer	5.45e-06	7.65e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GSTP1—stomach cancer	5.44e-06	7.64e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IRS2—stomach cancer	5.4e-06	7.57e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—TYMS—stomach cancer	5.37e-06	7.54e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—HMOX1—stomach cancer	5.37e-06	7.53e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IL6R—stomach cancer	5.36e-06	7.53e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PRKCB—stomach cancer	5.36e-06	7.52e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IL6ST—stomach cancer	5.34e-06	7.49e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—GSTM1—stomach cancer	5.31e-06	7.45e-05	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—PIK3CA—stomach cancer	5.28e-06	7.41e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—SERPINE1—stomach cancer	5.27e-06	7.4e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—MAPK1—stomach cancer	5.26e-06	7.39e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—EGFR—stomach cancer	5.26e-06	7.38e-05	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—PIK3CA—stomach cancer	5.25e-06	7.37e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—SERPINE1—stomach cancer	5.25e-06	7.36e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—APC—stomach cancer	5.24e-06	7.35e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CAV1—stomach cancer	5.23e-06	7.34e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—APOA1—stomach cancer	5.22e-06	7.33e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—KRAS—stomach cancer	5.22e-06	7.33e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—KRAS—stomach cancer	5.19e-06	7.29e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GSTT1—stomach cancer	5.14e-06	7.21e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—APC—stomach cancer	5.13e-06	7.2e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—RHOA—stomach cancer	5.09e-06	7.14e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CYP2A6—stomach cancer	5.08e-06	7.12e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—TYMS—stomach cancer	5.06e-06	7.1e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—RHOA—stomach cancer	5.06e-06	7.1e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PPARG—stomach cancer	5.04e-06	7.08e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—NOS3—stomach cancer	5.04e-06	7.07e-05	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—PIK3CA—stomach cancer	5.03e-06	7.06e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—SERPINE1—stomach cancer	5.02e-06	7.05e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—MAPK3—stomach cancer	5.02e-06	7.04e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—NOS3—stomach cancer	5.01e-06	7.03e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GSTM1—stomach cancer	5e-06	7.02e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—ERCC2—stomach cancer	4.99e-06	7e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PRKCB—stomach cancer	4.98e-06	6.99e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—KRAS—stomach cancer	4.97e-06	6.98e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IL6ST—stomach cancer	4.96e-06	6.96e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—ALB—stomach cancer	4.95e-06	6.94e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—AKR1C3—stomach cancer	4.94e-06	6.93e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—MAPK3—stomach cancer	4.91e-06	6.9e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IL6R—stomach cancer	4.87e-06	6.83e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—RHOA—stomach cancer	4.85e-06	6.8e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ENO1—stomach cancer	4.81e-06	6.75e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—PIK3CA—stomach cancer	4.8e-06	6.73e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—NOS3—stomach cancer	4.8e-06	6.73e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—MAPK1—stomach cancer	4.78e-06	6.7e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—EGFR—stomach cancer	4.77e-06	6.7e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—PIK3CA—stomach cancer	4.77e-06	6.7e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—APC—stomach cancer	4.77e-06	6.69e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IL6R—stomach cancer	4.76e-06	6.69e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—NOS3—stomach cancer	4.73e-06	6.64e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—ERBB2—stomach cancer	4.71e-06	6.61e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—ERCC2—stomach cancer	4.7e-06	6.6e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—MTHFR—stomach cancer	4.69e-06	6.58e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—ERBB2—stomach cancer	4.69e-06	6.57e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—MAPK1—stomach cancer	4.68e-06	6.56e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—EGFR—stomach cancer	4.67e-06	6.56e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—PIK3CA—stomach cancer	4.57e-06	6.41e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—MAPK3—stomach cancer	4.57e-06	6.41e-05	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—PIK3CA—stomach cancer	4.56e-06	6.4e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—SERPINE1—stomach cancer	4.56e-06	6.39e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—ALB—stomach cancer	4.53e-06	6.36e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—KRAS—stomach cancer	4.51e-06	6.33e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—ERBB2—stomach cancer	4.49e-06	6.29e-05	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—PIK3CA—stomach cancer	4.47e-06	6.27e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CXCL8—stomach cancer	4.47e-06	6.27e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—SERPINE1—stomach cancer	4.46e-06	6.26e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CXCL8—stomach cancer	4.44e-06	6.23e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—HRAS—stomach cancer	4.44e-06	6.23e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IL6R—stomach cancer	4.43e-06	6.21e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—MTHFR—stomach cancer	4.42e-06	6.2e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—KRAS—stomach cancer	4.42e-06	6.2e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—HRAS—stomach cancer	4.41e-06	6.19e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—RHOA—stomach cancer	4.4e-06	6.17e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CDKN1B—stomach cancer	4.36e-06	6.12e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—NOS3—stomach cancer	4.35e-06	6.1e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—MAPK1—stomach cancer	4.34e-06	6.1e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—EGFR—stomach cancer	4.34e-06	6.09e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CDKN1B—stomach cancer	4.34e-06	6.09e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—NOS3—stomach cancer	4.34e-06	6.09e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PTGS2—stomach cancer	4.33e-06	6.07e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CAV1—stomach cancer	4.33e-06	6.07e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—APOA1—stomach cancer	4.32e-06	6.06e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—RHOA—stomach cancer	4.3e-06	6.04e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CD44—stomach cancer	4.27e-06	5.99e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—NOS3—stomach cancer	4.26e-06	5.98e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CXCL8—stomach cancer	4.25e-06	5.97e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—IL6—stomach cancer	4.25e-06	5.96e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—HRAS—stomach cancer	4.23e-06	5.93e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—IL6—stomach cancer	4.23e-06	5.93e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CCND1—stomach cancer	4.16e-06	5.84e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CDKN1B—stomach cancer	4.15e-06	5.83e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—JUN—stomach cancer	4.15e-06	5.83e-05	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—PIK3CA—stomach cancer	4.15e-06	5.82e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—SERPINE1—stomach cancer	4.15e-06	5.82e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—PIK3CA—stomach cancer	4.14e-06	5.81e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CCND1—stomach cancer	4.14e-06	5.81e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—JUN—stomach cancer	4.13e-06	5.8e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—KRAS—stomach cancer	4.1e-06	5.76e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CAV1—stomach cancer	4.08e-06	5.72e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—APOA1—stomach cancer	4.07e-06	5.71e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—ERBB2—stomach cancer	4.07e-06	5.71e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—PIK3CA—stomach cancer	4.06e-06	5.69e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—IL6—stomach cancer	4.04e-06	5.68e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MMP9—stomach cancer	4.04e-06	5.67e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CDKN1A—stomach cancer	4.03e-06	5.65e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MMP9—stomach cancer	4.02e-06	5.64e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CDKN1A—stomach cancer	4e-06	5.62e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—RHOA—stomach cancer	4e-06	5.61e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—ERBB2—stomach cancer	3.98e-06	5.59e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PTGS2—stomach cancer	3.97e-06	5.57e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CCND1—stomach cancer	3.96e-06	5.56e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—NOS3—stomach cancer	3.96e-06	5.55e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—JUN—stomach cancer	3.95e-06	5.55e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MAPK8—stomach cancer	3.93e-06	5.51e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MAPK8—stomach cancer	3.91e-06	5.48e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CXCL8—stomach cancer	3.86e-06	5.41e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MMP9—stomach cancer	3.85e-06	5.4e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—HRAS—stomach cancer	3.83e-06	5.38e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CDKN1A—stomach cancer	3.83e-06	5.38e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PPARG—stomach cancer	3.81e-06	5.34e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CXCL8—stomach cancer	3.78e-06	5.3e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—PIK3CA—stomach cancer	3.77e-06	5.29e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CDKN1B—stomach cancer	3.77e-06	5.29e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—HRAS—stomach cancer	3.75e-06	5.27e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MAPK8—stomach cancer	3.74e-06	5.25e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—ERBB2—stomach cancer	3.7e-06	5.19e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CDKN1B—stomach cancer	3.69e-06	5.18e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—IL6—stomach cancer	3.67e-06	5.15e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PPP2R1A—stomach cancer	3.63e-06	5.09e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—VEGFA—stomach cancer	3.63e-06	5.09e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—VEGFA—stomach cancer	3.61e-06	5.06e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CCND1—stomach cancer	3.59e-06	5.04e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—IL6—stomach cancer	3.59e-06	5.04e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—STAT3—stomach cancer	3.59e-06	5.04e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—JUN—stomach cancer	3.59e-06	5.03e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PPARG—stomach cancer	3.59e-06	5.03e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—STAT3—stomach cancer	3.57e-06	5.01e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GSTP1—stomach cancer	3.56e-06	4.99e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CCND1—stomach cancer	3.52e-06	4.94e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—JUN—stomach cancer	3.51e-06	4.93e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—HMOX1—stomach cancer	3.51e-06	4.93e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CXCL8—stomach cancer	3.51e-06	4.93e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MMP9—stomach cancer	3.49e-06	4.9e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—HRAS—stomach cancer	3.49e-06	4.89e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CDKN1A—stomach cancer	3.48e-06	4.88e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—VEGFA—stomach cancer	3.45e-06	4.85e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MAPK3—stomach cancer	3.43e-06	4.82e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CDKN1B—stomach cancer	3.43e-06	4.81e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—ALB—stomach cancer	3.42e-06	4.8e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—STAT3—stomach cancer	3.42e-06	4.8e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MMP9—stomach cancer	3.42e-06	4.8e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MAPK3—stomach cancer	3.41e-06	4.79e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CDKN1A—stomach cancer	3.41e-06	4.78e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MAPK8—stomach cancer	3.39e-06	4.76e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PIK3CA—stomach cancer	3.38e-06	4.74e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—IL6—stomach cancer	3.34e-06	4.68e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MYC—stomach cancer	3.34e-06	4.68e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MAPK8—stomach cancer	3.32e-06	4.66e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MYC—stomach cancer	3.32e-06	4.66e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—TYMS—stomach cancer	3.31e-06	4.64e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—NOS3—stomach cancer	3.27e-06	4.59e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GSTM1—stomach cancer	3.27e-06	4.59e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CCND1—stomach cancer	3.27e-06	4.59e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MAPK3—stomach cancer	3.27e-06	4.59e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MAPK1—stomach cancer	3.27e-06	4.58e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—EGFR—stomach cancer	3.26e-06	4.58e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—JUN—stomach cancer	3.26e-06	4.58e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MAPK1—stomach cancer	3.25e-06	4.56e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—EGFR—stomach cancer	3.25e-06	4.56e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—ALB—stomach cancer	3.22e-06	4.52e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MYC—stomach cancer	3.18e-06	4.46e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MMP9—stomach cancer	3.18e-06	4.46e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CDKN1A—stomach cancer	3.16e-06	4.44e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—VEGFA—stomach cancer	3.13e-06	4.4e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MAPK1—stomach cancer	3.11e-06	4.36e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—EGFR—stomach cancer	3.11e-06	4.36e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—STAT3—stomach cancer	3.1e-06	4.35e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MAPK8—stomach cancer	3.09e-06	4.33e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—NOS3—stomach cancer	3.08e-06	4.33e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—KRAS—stomach cancer	3.08e-06	4.33e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ERCC2—stomach cancer	3.08e-06	4.32e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—VEGFA—stomach cancer	3.07e-06	4.31e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—KRAS—stomach cancer	3.07e-06	4.31e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—STAT3—stomach cancer	3.04e-06	4.26e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PTGS2—stomach cancer	2.99e-06	4.2e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MAPK3—stomach cancer	2.96e-06	4.16e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—KRAS—stomach cancer	2.94e-06	4.12e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MAPK3—stomach cancer	2.9e-06	4.07e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—MTHFR—stomach cancer	2.89e-06	4.06e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MYC—stomach cancer	2.88e-06	4.05e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—VEGFA—stomach cancer	2.85e-06	4e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PIK3CA—stomach cancer	2.83e-06	3.98e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MYC—stomach cancer	2.82e-06	3.96e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—STAT3—stomach cancer	2.82e-06	3.96e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MAPK1—stomach cancer	2.82e-06	3.96e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PTGS2—stomach cancer	2.82e-06	3.96e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—EGFR—stomach cancer	2.82e-06	3.96e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PIK3CA—stomach cancer	2.82e-06	3.96e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MAPK1—stomach cancer	2.76e-06	3.88e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—EGFR—stomach cancer	2.76e-06	3.87e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TP53—stomach cancer	2.74e-06	3.85e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TP53—stomach cancer	2.73e-06	3.83e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PIK3CA—stomach cancer	2.7e-06	3.79e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MAPK3—stomach cancer	2.7e-06	3.78e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CAV1—stomach cancer	2.67e-06	3.74e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—KRAS—stomach cancer	2.66e-06	3.74e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PIK3CA—stomach cancer	2.66e-06	3.74e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—APOA1—stomach cancer	2.66e-06	3.73e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MYC—stomach cancer	2.62e-06	3.68e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—HRAS—stomach cancer	2.62e-06	3.68e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TP53—stomach cancer	2.61e-06	3.66e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—KRAS—stomach cancer	2.61e-06	3.66e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—HRAS—stomach cancer	2.61e-06	3.66e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MAPK1—stomach cancer	2.57e-06	3.6e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—EGFR—stomach cancer	2.57e-06	3.6e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IL6—stomach cancer	2.51e-06	3.52e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—HRAS—stomach cancer	2.5e-06	3.5e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IL6—stomach cancer	2.5e-06	3.5e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PIK3CA—stomach cancer	2.45e-06	3.43e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PIK3CA—stomach cancer	2.44e-06	3.42e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—KRAS—stomach cancer	2.42e-06	3.4e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PIK3CA—stomach cancer	2.4e-06	3.36e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IL6—stomach cancer	2.39e-06	3.35e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TP53—stomach cancer	2.37e-06	3.32e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PPARG—stomach cancer	2.34e-06	3.29e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TP53—stomach cancer	2.32e-06	3.25e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—HRAS—stomach cancer	2.26e-06	3.18e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PIK3CA—stomach cancer	2.23e-06	3.12e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—HRAS—stomach cancer	2.22e-06	3.11e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IL6—stomach cancer	2.17e-06	3.04e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TP53—stomach cancer	2.15e-06	3.02e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IL6—stomach cancer	2.12e-06	2.98e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ALB—stomach cancer	2.11e-06	2.96e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—HRAS—stomach cancer	2.06e-06	2.89e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—NOS3—stomach cancer	2.02e-06	2.83e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IL6—stomach cancer	1.97e-06	2.77e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PTGS2—stomach cancer	1.84e-06	2.59e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PIK3CA—stomach cancer	1.84e-06	2.58e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PIK3CA—stomach cancer	1.74e-06	2.44e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PIK3CA—stomach cancer	1.13e-06	1.59e-05	CbGpPWpGaD
